ArticleEuropean journal of nuclear medicine and molecular imaging2025
CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [
Wei Tang, Ming Zhou, Chenxi Lu, Lin Qi, Ye Zhang, Yongxiang Tang, Xiaomei Gao, Shuo Hu, Yi Cai
Abstract read
In one paragraphArticle in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Wei Tang *Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0001-7411-3268 Ming Zhou *Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Chenxi Lu *Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Lin QiDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Ye ZhangDepartment of Oncology, NHC Key Laboratory of Cancer Proteomics, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0001-6692-2452 Yongxiang TangDepartment of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. xyyf0401@qq.com.ORCID 0000-0003-3987-8702 Xiaomei GaoDepartment of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. lswindy_2012@163.com.ORCID 0000-0002-9247-5825 Shuo HuDepartment of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. hushuo2018@163.com.ORCID 0000-0003-0998-8943 Yi CaiDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. cai-yi@csu.edu.cn.ORCID 0000-0001-7773-2064 Funding
China Postdoctoral Science Foundation 2022M23561Clinical Big Data System Construction Project Fund of Xiangya Hospital 33020125030Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA) 2020LNJJ01Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA) 2023LNJJ13Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA) 2023LNJJ16Fundamental Research Funds for the Central Universities of Central South University 2023ZZTS0551Fundamental Research Funds for the Central Universities of Central South University 2024ZZTS0870Key Program of Ministry of Industry and Information Technology of China CEIEC-2022-ZM02-0219Key Research and Development Program of Hunan Province 2023SK2017National Key Research and Development Plan 2017YFC0908004National Natural Science Foundation of China 81572524National Natural Science Foundation of China 81771873National Natural Science Foundation of China 81801740National Natural Science Foundation of China 81974397National Natural Science Foundation of China 82272045National Natural Science Foundation of China 82272907National Natural Science Foundation of China 82273121National Natural Science Foundation of China 91859207Outstanding Youth Fund Project of Hunan Province 2024JJ2090Outstanding Youth Fund Project of Hunan Province 2024JJ2094Science and Technology Innovation Program of Hunan Province 2021RC4056Xiangya Famous Doctor Fund of Central South University 33020123007
6 · The paper itselfAbstract
purposeApproximately 10% of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-negative, leading to blind spots in PSMA-based diagnosis. This study aimed to identify a potential target for PSMA-negative PCa and preliminarily evaluate the feasibility of using radionuclide probe targeting the identified target for PCa diagnosis.
methodsQuantitative protein analysis was performed on eight PSMA-negative PCa and eleven controls to identify a potential molecular target, followed by validation with an expanded cohort using immunohistochemistry. Sixteen participants underwent [
resultsQuantitative protein analysis revealed CD13 as the most significantly upregulated membrane protein in PSMA-negative PCa. Expanded validation results indicated that CD13 positivity rates were 92.9% (13/14), 82.7% (105/127), 91.7% (11/12), and 70% (14/20) in PSMA-negative PCa, PSMA-positive PCa, ductal adenocarcinoma of the prostate (DAC), and intraductal carcinoma of the prostate (IDC-P), respectively. In PCa participants, the median [
conclusionCD13 was a potential target for PSMA-negative PCa and also showed high positivity rates in PSMA-positive PCa, DAC, and IDC-P. [
Indexed as
CD13 AntigensGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProstatic NeoplasmsTheranostic NanomedicineAgedAntigens, SurfaceFluorine RadioisotopesHumansMaleMiddle AgedAntigens, SurfaceCD13 AntigensFluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IICD13 antigensClinical trialFOLH1 proteinPositron emission tomography computed tomographyProstatic neoplasms
What OpenQuestion holds
Textmetadata
Read underepoch 390